# Cannabinoid Clinical Trials: Cannabis-Induced Psychosis Risk > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-induced-psychosis-risk-clinical-trials/ > **Published:** 2026-03-04T12:00:45-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T12:00:54-04:00 > **Clinical Summary:** Explore cannabis-induced psychosis risk through clinical trials highlighting schizophrenia and bipolar disorder outcomes. --- #### Clinical Takeaway A significant portion of patients diagnosed with [cannabis-induced psychosis](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) go on to develop a primary psychiatric disorder such as schizophrenia spectrum disorder or [bipolar disorder](https://cedclinic.com/cannabis-induced-appetite-satiety-bypass-thc-brain/). Clinicians should treat cannabis-induced psychosis as a serious warning sign rather than a self-limited event, and close long-term psychiatric follow-up is warranted. Early identification and monitoring after a cannabis-induced psychosis episode may be critical to improving [patient outcomes](https://cedclinic.com/uk-medical-cannabis-chronic-pain-outcomes-patient-insights/). ### #24 Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis. **Citation:** Javed Mohammad Saad et al. *Prevalence of schizophrenia spectrum and [bipolar disorder](https://cedclinic.com/cannabis-induced-appetite-satiety-bypass-thc-brain/) among patients with cannabis induced psychosis: a [systematic review](https://cedclinic.com/cannabinoid-safety-efficacy-mental-health-study/) and meta-analysis.* BMC psychiatry. 2026. PMID: 41664079. **Study type:** Journal Article, Systematic Review, Meta-Analysis  |  **Topic area:** Psychosis  |  **CED Score:** 10 Design: 6 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: -2 **Quality Gate Alerts:** - Preclinical only **Abstract:** BACKGROUND: Distinguishing cannabis-induced psychosis from primary psychiatric disorders is difficult and has significant clinical and prognostic implications. Current treatment approaches lack standardized guidelines, potentially leading to the development of schizophrenia spectrum and bipolar disorder. This study systematically reviews the literature and provides a pooled prevalence of later developing these disorders following a cannabis-induced psychosis diagnosis. METHODS: We systematically reviewed Medline, Embase, Web of Science, Google Scholar, and PsychInfo for studies reporting on a group of patients with cannabis-induced psychosis and subsequent diagnoses of schizophrenia spectrum disorder, bipolar disorder, or both. The search was conducted until January 1, 2025. A modified version of the Newcastle-Ottawa scale was used to assess [study quality](https://cedclinic.com/cannabis-anxiety-study-quality-clinical-insights/). Random-effects meta-analyses were conducted to calculate pooled mean prevalence. Random-effects meta-regressions were used to identify predictors of higher prevalence. RESULTS: Our strategy identified 13 studies eligible for inclusion with a total population size of 7,515 which reported a total of 16 outcomes of interest. Among cannabis induced psychosis patients, 20% (95% CI:15.8-29.5%) later received a schizophrenia spectrum diagnosis, 5% (95% CI:2.7-6.9%) bipolar and 63% (95% CI:26.8-90.5%) unspecified (both). Compared to individuals receiving a later schizophrenia spectrum disorder diagnosis, patients were 76% less likely to develop bipolar disorder. Later diagnosis of an unspecified disorder showed an approximate 3 folds higher risk with an ARR of 2.52 (95% CI: 1.03-6.15) compared to schizophrenia spectrum disorder alone. CONCLUSIONS: Approximately one in five patients diagnosed with cannabis-induced psychosis will develop schizophrenia spectrum disorder, while one in twenty will be later diagnosed with bipolar disorder.  |   |  Further Reading Cannabis News[Teenage Cannabis Users Twice as Likely as Non-Users to Develop Psychosis](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) Cannabis Memes[College is hard lmao](https://cedclinic.com/college-is-hard-lmao/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) CED Clinic Blog[Smart Cannabis Dosing](https://cedclinic.com/smart-cannabis-dosing/) CED Clinic Blog[Cannabis Product Guide](https://cedclinic.com/cannabis-product-guide/) [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/41664079/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12922385/)[DOI ↗](https://doi.org/10.1186/s12888-025-07382-2) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabis Induced Psychosis: Systematic Review & Meta-Analysis on Schizophrenia Spectrum & Bipolar Disorder](https://cedclinic.com/cannabis-induced-psychosis-prevalence-schizophrenia-bipolar/) A comprehensive review analyzing the prevalence of schizophrenia and bipolar disorder following cannabis-induced psychosis. [Read the Meta-Analysis](https://cedclinic.com/cannabis-induced-psychosis-prevalence-schizophrenia-bipolar/) [`Cannabis-Induced Psychosis & Schizophrenia Risk: Key Research`](https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-progression-insights/) Key research findings on the relationship between cannabis-induced psychosis and schizophrenia risk. [Explore Key Research](https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-progression-insights/) [`Cannabis-Induced Psychosis and Psychotic Disorders: Key Evidence`](https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-progression-insights/) Evidence-based insights into cannabis-induced psychosis and its link to psychotic disorders. [View Evidence](https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-progression-insights/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Cannabinoid%20Clinical%20Trials%3A%20Cannabis-Induced%20Psychosis%20Risk&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-induced-psychosis-risk-clinical-trials%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-induced-psychosis-risk-clinical-trials%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Cannabinoid%20Clinical%20Trials%3A%20Cannabis-Induced%20Psychosis%20Risk%20https%3A%2F%2Fcedclinic.com%2Fcannabis-induced-psychosis-risk-clinical-trials%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).